Clinical Impact of Drug-Drug Interaction Between Aspirin and Prednisolone at a Cancer Center

Narendran Koomanan, Yu Ko, Wei Peng Yong, Raymond Ng, Yuet Peng Wong, Siew Woon Lim, Agus Salim, Alexandre Chan

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Adverse gastrointestinal (GI) events are complications in aspirin and prednisolone cotherapy. The prevalence of adverse GI events would be expected to be increased with cotherapy due to the overlapping toxicities of the 2 drugs. However, there is a dearth of literature investigating how often this interaction causes clinically important adverse GI events. Objectives: This retrospective study aimed to determine the prevalence of adverse GI events associated with the coadministration of aspirin and prednisolone. The use of gastroprotectant agents was also studied. Methods: The medical records of patients with cancer prescribed aspirin and prednisolone therapy between January 2007 and June 2011 were analyzed. The duration of aspirin-prednisolone overlap, prevalence of adverse GI events, and details on the concurrent use of other medications were evaluated. Results: The study included data from 142 patients (male, 64.8%; mean [SD] age, 67.4 [11.0] years). A total of 78.9% of the patients were on some form of gastroprotectant, the most common class of which was proton pump inhibitors. The prevalence of adverse GI events was 4.2% (6 patients). Four patients had presented with GI symptoms (abdominal pain, diarrhea, dysphagia, and vomiting); 3 patients had signs of GI injury (duodenal ulcers, iron deficiency anemia, and a Mallory-Weiss tear). The Naranjo algorithm classified 5 patients experienced possible adverse drug reactions (ADRs), and 1 as a probable ADR. Conclusion: Our study found that the prevalence of adverse GI events was low and managed to establish a weak association between the occurrence of events andthe coadministration of aspirin and prednisolone. This finding, together with the concurrent prescription of gastroprotectants, suggests that the clinical impact of the aspirin and prednisolone DDI is minimal.

Original languageEnglish
Pages (from-to)2259-2267
Number of pages9
JournalClinical Therapeutics
Volume34
Issue number12
DOIs
Publication statusPublished - 2012
Externally publishedYes

Fingerprint

Prednisolone
Drug Interactions
Aspirin
Pharmaceutical Preparations
Drug-Related Side Effects and Adverse Reactions
Neoplasms
Mallory-Weiss Syndrome
Iron-Deficiency Anemias
Proton Pump Inhibitors
Duodenal Ulcer
Deglutition Disorders
Abdominal Pain
Vomiting
Medical Records
Prescriptions
Diarrhea
Retrospective Studies
Cross-Sectional Studies
Wounds and Injuries

Keywords

  • Aspirin
  • Drug-drug interactions
  • Oncology
  • Prednisolone

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Clinical Impact of Drug-Drug Interaction Between Aspirin and Prednisolone at a Cancer Center. / Koomanan, Narendran; Ko, Yu; Yong, Wei Peng; Ng, Raymond; Wong, Yuet Peng; Lim, Siew Woon; Salim, Agus; Chan, Alexandre.

In: Clinical Therapeutics, Vol. 34, No. 12, 2012, p. 2259-2267.

Research output: Contribution to journalArticle

Koomanan, N, Ko, Y, Yong, WP, Ng, R, Wong, YP, Lim, SW, Salim, A & Chan, A 2012, 'Clinical Impact of Drug-Drug Interaction Between Aspirin and Prednisolone at a Cancer Center', Clinical Therapeutics, vol. 34, no. 12, pp. 2259-2267. https://doi.org/10.1016/j.clinthera.2012.11.002
Koomanan, Narendran ; Ko, Yu ; Yong, Wei Peng ; Ng, Raymond ; Wong, Yuet Peng ; Lim, Siew Woon ; Salim, Agus ; Chan, Alexandre. / Clinical Impact of Drug-Drug Interaction Between Aspirin and Prednisolone at a Cancer Center. In: Clinical Therapeutics. 2012 ; Vol. 34, No. 12. pp. 2259-2267.
@article{2b0a6373b85d44f1a2e239e8ada5d116,
title = "Clinical Impact of Drug-Drug Interaction Between Aspirin and Prednisolone at a Cancer Center",
abstract = "Background: Adverse gastrointestinal (GI) events are complications in aspirin and prednisolone cotherapy. The prevalence of adverse GI events would be expected to be increased with cotherapy due to the overlapping toxicities of the 2 drugs. However, there is a dearth of literature investigating how often this interaction causes clinically important adverse GI events. Objectives: This retrospective study aimed to determine the prevalence of adverse GI events associated with the coadministration of aspirin and prednisolone. The use of gastroprotectant agents was also studied. Methods: The medical records of patients with cancer prescribed aspirin and prednisolone therapy between January 2007 and June 2011 were analyzed. The duration of aspirin-prednisolone overlap, prevalence of adverse GI events, and details on the concurrent use of other medications were evaluated. Results: The study included data from 142 patients (male, 64.8{\%}; mean [SD] age, 67.4 [11.0] years). A total of 78.9{\%} of the patients were on some form of gastroprotectant, the most common class of which was proton pump inhibitors. The prevalence of adverse GI events was 4.2{\%} (6 patients). Four patients had presented with GI symptoms (abdominal pain, diarrhea, dysphagia, and vomiting); 3 patients had signs of GI injury (duodenal ulcers, iron deficiency anemia, and a Mallory-Weiss tear). The Naranjo algorithm classified 5 patients experienced possible adverse drug reactions (ADRs), and 1 as a probable ADR. Conclusion: Our study found that the prevalence of adverse GI events was low and managed to establish a weak association between the occurrence of events andthe coadministration of aspirin and prednisolone. This finding, together with the concurrent prescription of gastroprotectants, suggests that the clinical impact of the aspirin and prednisolone DDI is minimal.",
keywords = "Aspirin, Drug-drug interactions, Oncology, Prednisolone",
author = "Narendran Koomanan and Yu Ko and Yong, {Wei Peng} and Raymond Ng and Wong, {Yuet Peng} and Lim, {Siew Woon} and Agus Salim and Alexandre Chan",
year = "2012",
doi = "10.1016/j.clinthera.2012.11.002",
language = "English",
volume = "34",
pages = "2259--2267",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "12",

}

TY - JOUR

T1 - Clinical Impact of Drug-Drug Interaction Between Aspirin and Prednisolone at a Cancer Center

AU - Koomanan, Narendran

AU - Ko, Yu

AU - Yong, Wei Peng

AU - Ng, Raymond

AU - Wong, Yuet Peng

AU - Lim, Siew Woon

AU - Salim, Agus

AU - Chan, Alexandre

PY - 2012

Y1 - 2012

N2 - Background: Adverse gastrointestinal (GI) events are complications in aspirin and prednisolone cotherapy. The prevalence of adverse GI events would be expected to be increased with cotherapy due to the overlapping toxicities of the 2 drugs. However, there is a dearth of literature investigating how often this interaction causes clinically important adverse GI events. Objectives: This retrospective study aimed to determine the prevalence of adverse GI events associated with the coadministration of aspirin and prednisolone. The use of gastroprotectant agents was also studied. Methods: The medical records of patients with cancer prescribed aspirin and prednisolone therapy between January 2007 and June 2011 were analyzed. The duration of aspirin-prednisolone overlap, prevalence of adverse GI events, and details on the concurrent use of other medications were evaluated. Results: The study included data from 142 patients (male, 64.8%; mean [SD] age, 67.4 [11.0] years). A total of 78.9% of the patients were on some form of gastroprotectant, the most common class of which was proton pump inhibitors. The prevalence of adverse GI events was 4.2% (6 patients). Four patients had presented with GI symptoms (abdominal pain, diarrhea, dysphagia, and vomiting); 3 patients had signs of GI injury (duodenal ulcers, iron deficiency anemia, and a Mallory-Weiss tear). The Naranjo algorithm classified 5 patients experienced possible adverse drug reactions (ADRs), and 1 as a probable ADR. Conclusion: Our study found that the prevalence of adverse GI events was low and managed to establish a weak association between the occurrence of events andthe coadministration of aspirin and prednisolone. This finding, together with the concurrent prescription of gastroprotectants, suggests that the clinical impact of the aspirin and prednisolone DDI is minimal.

AB - Background: Adverse gastrointestinal (GI) events are complications in aspirin and prednisolone cotherapy. The prevalence of adverse GI events would be expected to be increased with cotherapy due to the overlapping toxicities of the 2 drugs. However, there is a dearth of literature investigating how often this interaction causes clinically important adverse GI events. Objectives: This retrospective study aimed to determine the prevalence of adverse GI events associated with the coadministration of aspirin and prednisolone. The use of gastroprotectant agents was also studied. Methods: The medical records of patients with cancer prescribed aspirin and prednisolone therapy between January 2007 and June 2011 were analyzed. The duration of aspirin-prednisolone overlap, prevalence of adverse GI events, and details on the concurrent use of other medications were evaluated. Results: The study included data from 142 patients (male, 64.8%; mean [SD] age, 67.4 [11.0] years). A total of 78.9% of the patients were on some form of gastroprotectant, the most common class of which was proton pump inhibitors. The prevalence of adverse GI events was 4.2% (6 patients). Four patients had presented with GI symptoms (abdominal pain, diarrhea, dysphagia, and vomiting); 3 patients had signs of GI injury (duodenal ulcers, iron deficiency anemia, and a Mallory-Weiss tear). The Naranjo algorithm classified 5 patients experienced possible adverse drug reactions (ADRs), and 1 as a probable ADR. Conclusion: Our study found that the prevalence of adverse GI events was low and managed to establish a weak association between the occurrence of events andthe coadministration of aspirin and prednisolone. This finding, together with the concurrent prescription of gastroprotectants, suggests that the clinical impact of the aspirin and prednisolone DDI is minimal.

KW - Aspirin

KW - Drug-drug interactions

KW - Oncology

KW - Prednisolone

UR - http://www.scopus.com/inward/record.url?scp=84984559334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984559334&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2012.11.002

DO - 10.1016/j.clinthera.2012.11.002

M3 - Article

C2 - 23200184

AN - SCOPUS:84984559334

VL - 34

SP - 2259

EP - 2267

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 12

ER -